It was also significantly higher than that of CD4+ PBMCs from esophageal cancer patients (76.83 ± 2.565% vs. 62.80 ± 2.882%, p < 0.0001; 62.80 ± 2.882% vs. 35.75 ± 35.75%, p = 0.0001; Figure 4B). Here, CD4 is linked to esophageal cancer.